DAFNA Capital Management LLC Invests $288,000 in Conatus Pharmaceuticals Inc. (CNAT)
DAFNA Capital Management LLC acquired a new stake in shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 50,000 shares of the biotechnology company’s stock, valued at approximately $288,000. DAFNA Capital Management LLC owned approximately 0.17% of Conatus Pharmaceuticals as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Conatus Pharmaceuticals by 323.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 62,977 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 48,090 shares in the last quarter. Numeric Investors LLC acquired a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter valued at $1,620,000. Voya Investment Management LLC acquired a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter valued at $101,000. OxFORD Asset Management LLP bought a new position in Conatus Pharmaceuticals during the 2nd quarter worth $230,000. Finally, EAM Investors LLC bought a new position in Conatus Pharmaceuticals during the 2nd quarter worth $361,000. 33.13% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “DAFNA Capital Management LLC Invests $288,000 in Conatus Pharmaceuticals Inc. (CNAT)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/dafna-capital-management-llc-invests-288000-in-conatus-pharmaceuticals-inc-cnat/1613003.html.
Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) traded up 4.62% on Friday, reaching $5.89. The company had a trading volume of 418,825 shares. The company’s market capitalization is $176.72 million. The company’s 50-day moving average is $5.52 and its 200-day moving average is $5.81. Conatus Pharmaceuticals Inc. has a one year low of $1.45 and a one year high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $9.33 million. During the same period last year, the firm posted ($0.30) EPS. Equities research analysts predict that Conatus Pharmaceuticals Inc. will post ($0.45) earnings per share for the current year.
CNAT has been the subject of several analyst reports. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 target price on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Finally, Seaport Global Securities initiated coverage on Conatus Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $16.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $16.17.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Want to see what other hedge funds are holding CNAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT).
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.